Table 3 Subgroup analysis of survival between two groups of BTC patients undergoing R0 resection
Variable | 5-year OS rate (%) | P value | 3-year RFS rate (%) | P value | ||
|---|---|---|---|---|---|---|
Adjuvant chemotherapy | Observation | Adjuvant chemotherapy | Observation | |||
Tumor location | ||||||
Gall bladder | 62.5 | 52.3 | 0.057 | 69.7 | 58.1 | 0.148 |
Bile duct | 35.2 | 26.9 | 0.577 | 30.8 | 12.5 | 0.720 |
Intrahepatic bile duct | 27.5 | 0 | 0.265 | 22.8 | 32.5 | 0.549 |
Distal bile duct | 72.9 | 50.0 | 0.014 | 70.0 | 25.0 | 0.016 |
Perihilar bile duct | 0 | 66.7 | 0.139 | 0 | 33.3 | 0.066 |
Age (years) | ||||||
<65 | 50.3 | 62.1 | 0.723 | 49.4 | 25.3 | 0.479 |
≥65 | 45.8 | 25.2 | 0.570 | 48.6 | 41.2 | 0.508 |
Lymph node involvement | ||||||
Yes | 23.0 | 23.8 | 0.121 | 21.7 | 15.6 | 0.222 |
No | 57.9 | 39.6 | 0.587 | 59.3 | 44.2 | 0.336 |
CA 19-9 level (U/mL) a | ||||||
<37 | 58.7 | 75.6 | 0.195 | 62.1 | 76.7 | 0.430 |
≥37 | 34.8 | 27.9 | 0.196 | 32.3 | 0 | 0.158 |
Histologic differentiation b | ||||||
W/D | 71.3 | 73.5 | 0.741 | 68.9 | 60.3 | 0.519 |
M/D or P/D | 36.6 | 29.0 | 0.476 | 39.7 | 24.9 | 0.325 |